At its March 2025 meeting, the Pharmaceutical Benefits Advisory Committee (PBAC) reviewed two proposed extensions to existing cystic fibrosis treatments. Both have been recommended for listing:
Trikafta: Proposed Extension to include children aged 2 years and older with a responsive CFTR gene mutation.
This recommendation has the potential to give 45 children access to a CFTR modulator therapy for the first time. Additionally, approximately 200 individuals currently using Symdeko or Kalydeco may become eligible to transition to Trikafta, offering broader treatment options.
Kalydeco: Proposed Extension to include infants aged 1 to 4 months with at least one CFTR gene mutation responsive to Ivacaftor.
This expansion would enable early intervention for approximately 10 babies each year—providing a crucial opportunity to impact health outcomes in the earliest months of life.
More information here.